Piper Sandler Reiterates Overweight on Axsome Therapeutics, Maintains $258 Price Target
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsReiterationPrice Target
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.
Piper Sandler analyst David Amsellem reiterates Axsome Therapeutics (NASDAQ:AXSM) with a Overweight and maintains $258 price target.